Tim Anderson
Stock Analyst at B of A Securities
(4.07)
# 480
Out of 4,906 analysts
35
Total ratings
70%
Success rate
9.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Neutral | $161 → $175 | $164.36 | +6.47% | 6 | Jul 17, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Underperform | $575 → $547 | $545.53 | +0.27% | 2 | Apr 17, 2025 | |
| AARD Aardvark Therapeutics | Maintains: Buy | $22 → $26 | $12.05 | +115.77% | 2 | Mar 27, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $116 → $126 | $108.28 | +16.36% | 3 | Mar 5, 2025 | |
| AMGN Amgen | Maintains: Underperform | $275 → $294 | $295.87 | -0.63% | 4 | Mar 5, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $200 → $223 | $184.85 | +20.64% | 5 | Mar 4, 2025 | |
| MTSR Metsera | Initiates: Buy | $38 | $39.84 | -4.62% | 1 | Feb 25, 2025 | |
| MRNA Moderna | Maintains: Underperform | $41 → $34 | $30.97 | +9.78% | 2 | Feb 11, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $118 → $112 | $79.31 | +41.22% | 4 | Feb 5, 2025 | |
| PFE Pfizer | Reinstates: Neutral | $29 | $24.26 | +19.54% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $63 | $46.69 | +34.93% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $178 | $122.68 | +45.09% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $997 | $762.18 | +30.81% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $114.14 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $68.72 | - | 1 | Sep 22, 2017 |
Johnson & Johnson
Jul 17, 2025
Maintains: Neutral
Price Target: $161 → $175
Current: $164.36
Upside: +6.47%
Regeneron Pharmaceuticals
Apr 17, 2025
Maintains: Underperform
Price Target: $575 → $547
Current: $545.53
Upside: +0.27%
Aardvark Therapeutics
Mar 27, 2025
Maintains: Buy
Price Target: $22 → $26
Current: $12.05
Upside: +115.77%
Gilead Sciences
Mar 5, 2025
Maintains: Buy
Price Target: $116 → $126
Current: $108.28
Upside: +16.36%
Amgen
Mar 5, 2025
Maintains: Underperform
Price Target: $275 → $294
Current: $295.87
Upside: -0.63%
AbbVie
Mar 4, 2025
Maintains: Neutral
Price Target: $200 → $223
Current: $184.85
Upside: +20.64%
Metsera
Feb 25, 2025
Initiates: Buy
Price Target: $38
Current: $39.84
Upside: -4.62%
Moderna
Feb 11, 2025
Maintains: Underperform
Price Target: $41 → $34
Current: $30.97
Upside: +9.78%
Merck & Co.
Feb 5, 2025
Maintains: Buy
Price Target: $118 → $112
Current: $79.31
Upside: +41.22%
Pfizer
Dec 10, 2024
Reinstates: Neutral
Price Target: $29
Current: $24.26
Upside: +19.54%
Dec 10, 2024
Reinstates: Neutral
Price Target: $63
Current: $46.69
Upside: +34.93%
Dec 10, 2024
Reinstates: Neutral
Price Target: $178
Current: $122.68
Upside: +45.09%
Dec 10, 2024
Reinstates: Buy
Price Target: $997
Current: $762.18
Upside: +30.81%
May 9, 2022
Downgrades: Peer Perform
Price Target: n/a
Current: $114.14
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $68.72
Upside: -